Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on Monday. The ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) is a global leader in medical technology ...

Shares of Becton Dickinson & Co. BDX slipped 1.60% to $225.85 Wednesday, on what proved to be an all-around rough trading ...

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Business: Becton Dickinson develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products for health-care institutions, physicians, life science ...

Shares of Becton Dickinson & Co. BDX slid 7.28% to $227.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...